Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Rexahn Pharmaceuticals Inc (NYSE American:RNN)

1.92
Delayed Data
As of Dec 15
 -0.02 / -1.03%
Today’s Change
1.27
Today|||52-Week Range
7.10
+35.31%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$60.9M

Company Description

Rexahn Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It dedicates to the discovery, development and commercialization of innovative treatments for cancer and other medical needs. The firm have three clinical stage oncology candidates: Archexin, RX-3117, and Supinoxin and a robust pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D gold and times. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Contact Information

Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road
Rockville Maryland 20850
P:(240) 268-5300
Investor Relations:

Employees

Shareholders

Mutual fund holders3.56%
Other institutional2.22%
Individual stakeholders0.05%

Top Executives

Peter David SuzdakChief Executive Officer & Director
Tae Heum JeongChief Financial Officer, Secretary & Senior VP
Ely BenaimChief Medical Officer
Lisa M. NolanChief Business Officer